Paul A Bunn

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. pmc The evolution of tumor classification: a role for genomics?
    Paul A Bunn
    Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado, Denver, Aurora, CO 80045, USA Electronic address
    Cancer Cell 24:693-4. 2013
  2. doi request reprint Worldwide overview of the current status of lung cancer diagnosis and treatment
    Paul A Bunn
    Division of Medical Oncology, University of Colorado, Aurora, CO 80045, USA
    Arch Pathol Lab Med 136:1478-81. 2012
  3. ncbi request reprint Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines
    Christopher D Coldren
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, C272, Denver, 80262, USA
    Mol Cancer Res 4:521-8. 2006
  4. ncbi request reprint Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels
    Barbara A Helfrich
    Tobacco Related Malignancy Program, University of Colorado Cancer Center, Aurora, CO 80010, USA
    Clin Cancer Res 12:7117-25. 2006
  5. pmc Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression
    Rafal Dziadziuszko
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 28:2174-80. 2010
  6. ncbi request reprint The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer
    David Raben
    Tobacco Related Malignancy Program, Department of Radiation Oncology, Anschutz Cancer Pavilion, University of Colorado Health Sciences Center, 1165 North Ursula Street F706, Aurora, CO 80010 0510, USA
    Clin Cancer Res 11:795-805. 2005
  7. doi request reprint Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity
    Tim Byers
    School of Medicine, University of Colorado Comprehensive Cancer Center, 13001 East 17th Place, Aurora, CO 80045, USA
    Cancer Epidemiol Biomarkers Prev 17:158-62. 2008
  8. ncbi request reprint Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 24:5034-42. 2006
  9. ncbi request reprint Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients
    Federico Cappuzzo
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80010, USA
    J Clin Oncol 23:5007-18. 2005
  10. pmc EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort
    Marileila Varella-Garcia
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80045, USA
    J Thorac Oncol 4:318-25. 2009

Detail Information

Publications66

  1. pmc The evolution of tumor classification: a role for genomics?
    Paul A Bunn
    Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado, Denver, Aurora, CO 80045, USA Electronic address
    Cancer Cell 24:693-4. 2013
    ....
  2. doi request reprint Worldwide overview of the current status of lung cancer diagnosis and treatment
    Paul A Bunn
    Division of Medical Oncology, University of Colorado, Aurora, CO 80045, USA
    Arch Pathol Lab Med 136:1478-81. 2012
    ..An increasing percentage of patients with advanced lung cancer have molecular drivers in genes for which oral tyrosine kinase inhibitors have been developed...
  3. ncbi request reprint Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines
    Christopher D Coldren
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, C272, Denver, 80262, USA
    Mol Cancer Res 4:521-8. 2006
    ..Some of these genes could be targets of pharmacologic interventions to overcome primary resistance...
  4. ncbi request reprint Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels
    Barbara A Helfrich
    Tobacco Related Malignancy Program, University of Colorado Cancer Center, Aurora, CO 80010, USA
    Clin Cancer Res 12:7117-25. 2006
    ..Downstream cell cycle and signaling events were compared with growth-inhibitory effects...
  5. pmc Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression
    Rafal Dziadziuszko
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 28:2174-80. 2010
    ....
  6. ncbi request reprint The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer
    David Raben
    Tobacco Related Malignancy Program, Department of Radiation Oncology, Anschutz Cancer Pavilion, University of Colorado Health Sciences Center, 1165 North Ursula Street F706, Aurora, CO 80010 0510, USA
    Clin Cancer Res 11:795-805. 2005
    ..In this report, we investigated the cellular and molecular effects of cetuximab alone and in combination with radiation and/or chemotherapy in human NSCLC cell lines with varying levels of EGFR overexpression in vitro and in vivo...
  7. doi request reprint Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity
    Tim Byers
    School of Medicine, University of Colorado Comprehensive Cancer Center, 13001 East 17th Place, Aurora, CO 80045, USA
    Cancer Epidemiol Biomarkers Prev 17:158-62. 2008
    ..Radiologic imaging may be more sensitive for peripheral cancers than for cancers arising in the central airways, from which bronchial epithelial cells are exfoliated into the sputum...
  8. ncbi request reprint Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 24:5034-42. 2006
    ..We analyzed ISEL tumor biopsy samples to examine relationships between biomarkers and clinical outcome after gefitinib treatment in a placebo-controlled setting...
  9. ncbi request reprint Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients
    Federico Cappuzzo
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80010, USA
    J Clin Oncol 23:5007-18. 2005
    ..Preclinical data indicate that HER2, a member of the EGFR family, could enhance TKI sensitivity...
  10. pmc EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort
    Marileila Varella-Garcia
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80045, USA
    J Thorac Oncol 4:318-25. 2009
    ..This study was carried out to verify whether EGFR FISH had similar performance in Japanese patients...
  11. doi request reprint First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay
    Fred R Hirsch
    Division of Medical Oncology, University of Colorado, Health Sciences Center, Aurora, CO, USA
    J Thorac Oncol 3:S138-42. 2008
    ....
  12. ncbi request reprint Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer
    Rafal Dziadziuszko
    University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Clin Cancer Res 12:3078-84. 2006
    ....
  13. ncbi request reprint High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia
    Timothy C Kennedy
    University of Colorado Comprehensive Cancer Center, University of Colorado Health Sciences Center, Denver, CO, USA
    Lung Cancer 49:187-91. 2005
    ..Seven additional subjects had severe dysplasia found on endobronchial biopsy. Moderate sputum atypia may be an important marker of risk for occult endobronchial malignancy in high risk subjects...
  14. ncbi request reprint Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma
    Barbara A Frederick
    Departments of Radiation, University of Colorado at Denver Health Sciences Center, Aurora, Colorado 80010, USA
    Mol Cancer Ther 6:1683-91. 2007
    ....
  15. pmc Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
    Andrew J Weickhardt
    Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Colorado 80045, USA
    J Thorac Oncol 7:1807-14. 2012
    ....
  16. ncbi request reprint Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study
    Fred R Hirsch
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Clin Oncol 23:6838-45. 2005
    ..Epidermal growth factor receptor (EGFR) inhibitors demonstrated response rates of 20% to 30% in patients with advanced BAC subtypes, but selection methods for patient therapy are not established...
  17. ncbi request reprint Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Federico Cappuzzo
    University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, CO 80010, USA
    J Natl Cancer Inst 97:643-55. 2005
    ..We carried out a clinical study to compare the relationship between EGFR gene copy number, EGFR protein expression, EGFR mutations, and Akt activation status as predictive markers for gefitinib therapy in advanced NSCLC...
  18. ncbi request reprint Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
    Samir E Witta
    Department of Medicine Medical Oncology, University of Colorado Health Sciences Center and University of Colorado Cancer Center, Campus Box 8117, PO Box 6511, Aurora, CO 80045, USA
    Cancer Res 66:944-50. 2006
    ..Thus, combined HDAC inhibitor and gefitinib treatment represents a novel pharmacologic strategy for overcoming resistance to EGFR inhibitors in patients with lung cancer...
  19. ncbi request reprint Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists
    John M Stewart
    Department of Biochemistry and Molecular Genetics, Cancer Center, and Pulmonary Hypertension Center, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Peptides 26:1288-91. 2005
    ..In certain combinations, they act synergistically with standard anti-cancer drugs. Due to its structure and biological activity, BKM-570 is an attractive lead compound for derivatization and evaluation for lung and prostate cancer drugs...
  20. ncbi request reprint Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors
    Daniel C Chan
    University of Colorado Cancer Center, Department of Medicine, Preventive Medicine and Biostatistics, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Clin Cancer Res 8:904-12. 2002
    ..0001), and increased apoptosis (P = < 0.001) when compared with control animals. These results provide rationale for conducting clinical trials using the combination of exisulind and docetaxel in patients with advanced lung cancer...
  21. ncbi request reprint Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines
    Fred R Hirsch
    Department of Medicine, University of Colorado Cancer Center and the University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Breast Cancer 3:12-6. 2002
    ..These preclinical studies indicate a need to study the clinical synergistic effects of the gemcitabine/trastuzumab combination in breast cancer and NSCLC patients whose tumors overexpress HER2/ neu...
  22. ncbi request reprint Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report
    Rafal Dziadziuszko
    Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
    J Thorac Oncol 2:91-2. 2007
    ..Molecular characterization of the primary tumor before any treatment is provided, and mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors are briefly discussed...
  23. ncbi request reprint Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer
    Paul A Bunn
    Departments of Medicine and Pathology, The University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Semin Oncol 29:38-44. 2002
    ..Response rates appear higher when the inhibitors are combined with chemotherapy. The results of randomized trials comparing the use of chemotherapy alone with chemotherapy plus the inhibitors are eagerly awaited...
  24. pmc Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, Aurora, CO 80045, USA
    Clin Cancer Res 14:6317-23. 2008
    ..Here, we assess the value of using epidermal growth factor receptor (EGFR) gene copy number in tumor biopsy samples, as determined by fluorescence in situ hybridization (FISH), as a predictor of treatment outcome...
  25. ncbi request reprint Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer
    Christiane D Thienelt
    Division of Medical Oncology and Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    J Clin Oncol 23:8786-93. 2005
    ..Secondary objectives included efficacy and paclitaxel and carboplatin pharmacokinetics during cetuximab treatment...
  26. pmc Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model
    Robert S Stearman
    Department of Medicine Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, USA
    Am J Pathol 167:1763-75. 2005
    ..Thus, the A/J mouse-urethane model reflects significant molecular details of human lung AC, and comparison of changes in orthologous gene expression may provide novel insights into lung carcinogenesis...
  27. doi request reprint Endobronchial miRNAs as biomarkers in lung cancer chemoprevention
    Celine Mascaux
    Department of Medicine, Division of Medical Oncology, Colorado School of Public Health, Aurora, 80045, USA
    Cancer Prev Res (Phila) 6:100-8. 2013
    ..Mir-34c changes at follow-up could be used as a quantitative biomarker that parallels histologic response in formalin-fixed bronchial biopsies in future lung cancer chemoprevention studies...
  28. ncbi request reprint Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy
    Paul A Bunn
    Department of Medicine, University of Colorado Cancer Center and University of Colorado Health Sciences Center, Aurora, 80045, USA
    Clin Cancer Res 12:3652-6. 2006
  29. pmc Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer
    Fred R Hirsch
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
    Cancer 112:1114-21. 2008
    ..Two different antibodies, scoring systems, and cutoff points of epidermal growth factor receptor (EGFR) protein expression were compared to predict response and survival of enrolled patients...
  30. ncbi request reprint From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer
    Glen J Weiss
    Developmental Therapeutics Program, Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA
    Oncology (Williston Park) 20:1515-24; discussion 1524-5, 1530, 1535. 2006
    ..Together, these developments have moved us away from the nihilism of 20 years ago into an era of unprecedented optimism in taking on the many remaining challenges of managing NSCLC in the 21st century...
  31. pmc A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, 12801 E 17th Ave, Aurora, CO 80045, USA
    J Clin Oncol 29:3567-73. 2011
    ....
  32. ncbi request reprint Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer
    Glen J Weiss
    University of Colorado Health Sciences Center, Division of Medical Oncology Center, Aurora, CO 80010, USA
    J Clin Oncol 24:4405-11. 2006
    ..However, few published data exist on the efficacy and tolerability of second-line cytotoxic therapy in this population...
  33. ncbi request reprint Bronchial epithelial Ki-67 index is related to histology, smoking, and gender, but not lung cancer or chronic obstructive pulmonary disease
    York E Miller
    Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, Denver Veterans Affairs Medical Center, University of Colorado at Denver, Denver, Colorado 80220, USA
    Cancer Epidemiol Biomarkers Prev 16:2425-31. 2007
    ..To determine whether increased bronchial epithelial proliferation is associated with histology, smoking status, gender, age, chronic obstructive pulmonary disease (COPD), or lung cancer...
  34. pmc A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer
    Karen Kelly
    Pulmonary 111A, Denver VA Medical Center, 1055 Clermont Street, Denver, CO 80220, USA
    Cancer Prev Res (Phila) 2:440-9. 2009
    ..Agents advancing to phase III randomized trials should produce greater histologic changes. The addition of alpha tocopherol did not affect toxicity...
  35. doi request reprint Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction
    Paul A Bunn
    University of Colorado Cancer Center, Aurora, Colorado, USA
    Oncologist 13:1-4. 2008
    ..In fact, many commonly used chemotherapeutic drugs have antiangiogenic activity. Ongoing studies are focusing on patient selection and targeted therapies, and there are many new agents undergoing clinical trials...
  36. ncbi request reprint Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study
    Fumiko Taguchi
    Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6838, USA
    J Natl Cancer Inst 99:838-46. 2007
    ....
  37. ncbi request reprint New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
    Robert C Doebele
    University of Colorado Cancer Center, Division of Medical Oncology, Aurora, CO, USA
    Lung Cancer 69:1-12. 2010
    ....
  38. ncbi request reprint Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis
    Fred R Hirsch
    Department of Pathology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Clin Oncol 21:3798-807. 2003
    ..The molecular mechanisms responsible for EGFR overexpression are poorly understood...
  39. ncbi request reprint Lack of association between sputum atypia and chronic obstructive pulmonary disease mortality
    York E Miller
    Denver Veterans Affairs Medical Center, Denver, Colorado 80220 3808, USA
    J Thorac Oncol 1:302-7. 2006
    ..The authors hypothesized that sputum atypia would reflect the processes leading to progressive airflow obstruction and might be a novel biomarker of more rapidly progressive COPD...
  40. ncbi request reprint HER2/neu expression in malignant lung tumors
    Fred R Hirsch
    Lung Cancer Program, Department of Pathology, University of Colorado Cancer Center, Denver, CO 80262, USA
    Semin Oncol 29:51-8. 2002
    ..Future studies in NSCLC need to include immunohistochemistry and fluorescence in situ hybridization analysis to determine the method of choice for evaluating clinically relevant HER2/neu-positive tumors...
  41. ncbi request reprint Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer
    Glen J Weiss
    Division of Medical Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Clin Lung Cancer 8:335-8. 2007
    ..The addition of bevacizumab to carboplatin/paclitaxel in the first-line setting was shown to improve survival and response. We assessed pemetrexed and bevacizumab compared with pemetrexed alone in the salvage setting...
  42. pmc Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
    Robert C Doebele
    Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4502-11. 2012
    ..It is hypothesized that the dominant oncogene in NSCLC would be associated with distinct patterns of metastatic spread in NSCLC at the time of diagnosis...
  43. ncbi request reprint Ongoing and future trials of biologic therapies in lung cancer
    Paul A Bunn
    University of Colorado Cancer Center, Denver, CO, USA
    Lung Cancer 41:S175-86. 2003
    ..Many new agents have been developed to attack these targets. This article describes current and proposed trials for these new targeted therapies in both small cell and non-small cell lung cancers...
  44. ncbi request reprint Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective
    David Raben
    Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, USA
    Int J Radiat Oncol Biol Phys 59:27-38. 2004
    ..This article will focus on the biology, rationale, and preclinical studies with targeted anti-EGFR and antiangiogenic therapies for the management of NSCLC...
  45. pmc Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
    Cancer 119:2383-90. 2013
    ..The detailed etiology of the effect, its symptomatic significance, and the effectiveness of subsequent testosterone replacement have not been previously reported...
  46. ncbi request reprint Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors)
    Paul A Bunn
    Lung Cancer Program and Department of Medicine, University of Colorado Cancer Center and University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Semin Oncol 29:17-22. 2002
    ....
  47. ncbi request reprint ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer
    David Raben
    Department of Radiation Oncology, University of Colorado Comprehensive Cancer Center, Denver, CO 80010 0510, USA
    Semin Oncol 29:37-46. 2002
    ..Future studies will certainly combine ZD1839 with chemotherapy or radiation. ZD1839 also may be effective as a chemoprevention agent because premalignant lesions often overexpress epidermal growth factor receptor...
  48. ncbi request reprint Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know
    David Raben
    University of Colorado Cancer Center, Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, CO 80010 5010, USA
    Lung Cancer 41:S15-22. 2003
    ....
  49. ncbi request reprint High prevalence of endobronchial malignancy in high-risk patients with moderate dysplasia in sputum
    Timothy C Kennedy
    Specialized Program of Research Excellence SPORE in Lung Cancer, University of Colorado Cancer Center, Denver, CO 80218, USA
    Chest 125:109S. 2004
  50. ncbi request reprint The potential role of proteasome inhibitors in the treatment of lung cancer
    Paul A Bunn
    University of Colorado Cancer Center, Denver, Colorado, USA
    Clin Cancer Res 10:4263s-4265s. 2004
    ..A number of Phase I combination studies are also underway. Hopefully, bortezomib will show sufficient activity in lung cancer to improve survival in this dread disease...
  51. ncbi request reprint Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy
    Paul A Bunn
    University of Colorado Cancer Center, Denver, CO, USA
    Clin Lung Cancer 6:85-98. 2004
    ..In addition, biologically targeted agents are currently under study for patients with advanced NSCLC...
  52. doi request reprint Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy
    Samir E Witta
    University of Colorado Cancer Center, 12801 E 17th Ave, Mail Stop 8117, Aurora, CO 80045, USA
    J Clin Oncol 30:2248-55. 2012
    ..This randomized phase II study evaluated the outcome of erlotinib with and without the isoform selective HDACi, entinostat...
  53. doi request reprint Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion
    Paul A Bunn
    University of Colorado Cancer Center, Aurora, Colorado, USA
    Oncologist 13:37-46. 2008
    ....
  54. ncbi request reprint Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction
    Sheila A Prindiville
    Department of Medicine, School of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer Epidemiol Biomarkers Prev 12:987-93. 2003
    ....
  55. ncbi request reprint Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?
    Paul A Bunn
    University of Colorado Cancer Center, Denver, CO 80262, USA
    J Clin Oncol 20:23S-33S. 2002
    ..Some of these two-drug combinations may be acceptable in selected patients with a performance status of 2. Newer, targeted therapies hold promise to improve outcome without adding a great deal of additional toxicity...
  56. pmc Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition
    Matias Casás-Selves
    Department of Biochemistry and Molecular Genetics, Program in Molecular Biology, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
    Cancer Res 72:4154-64. 2012
    ..Targeting the Wnt-tankyrase-β-catenin pathway together with EGFR inhibition may improve clinical outcome in patients with NSCLC...
  57. ncbi request reprint Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer
    Paul A Bunn
    University of Colorado Cancer Center, Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Semin Oncol 29:87-94. 2002
    ..These observations lead to the studies of the combination of exisulind and docetaxel in preclinical and clinical studies in human lung cancer described in this article...
  58. ncbi request reprint Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent
    Benjamin Solomon
    University of Colorado Cancer Center, Aurora, CO 80045, USA
    Future Oncol 1:733-46. 2005
    ..Clinical trials of pemetrexed alone or in combination with other chemotherapeutic agents have shown considerable activity in many tumor types including colorectal, pancreatic and breast cancer, and urothelial tumors...
  59. ncbi request reprint Expression of target molecules in lung cancer: challenge for a new treatment paradigm
    Fred R Hirsch
    University of Colorado Cancer Center and Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Semin Oncol 29:2-8. 2002
    ....
  60. ncbi request reprint Adjuvant chemotherapy for resected non-small-cell lung cancer
    Benjamin Solomon
    Medical Oncology Fellow, University of Colorado, Health Sciences Center, Denver, USA
    Oncology (Williston Park) 19:1685-97; discussion 1698-700, 1705. 2005
    ....
  61. ncbi request reprint Bradykinin antagonists as new drugs for prostate cancer
    John M Stewart
    Department of Biochemistry, University of Colorado School of Medicine, Denver, CO 80262, USA
    Int Immunopharmacol 2:1781-6. 2002
    ..This class of compounds offers hope for development of new drugs for refractory prostate cancer...
  62. ncbi request reprint Early-stage NSCLC: the role of radiotherapy and systemic therapy
    Paul A Bunn
    Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Denver, Colorado 80045, USA
    J Natl Compr Canc Netw 2:S31-40. 2004
    ..Ongoing trials continue to assess the role of preoperative and postoperative chemotherapy or radiotherapy in early stage non-small cell lung cancer...
  63. pmc Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells
    Lindsay Marek
    Department of Craniofacial Biology, University of Colorado at Denver Anschutz Medical Campus, Aurora, CO 80045, USA
    Mol Pharmacol 75:196-207. 2009
    ..Thus, FGF2, FGF9 and their respective high-affinity FGFRs comprise a growth factor autocrine loop that is active in a subset of gefitinib-insensitive NSCLC cell lines...
  64. doi request reprint The tissue is the issue: personalized medicine for non-small cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Clin Cancer Res 16:4909-11. 2010
    ..Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed...
  65. ncbi request reprint Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
    Clin Cancer Res 12:4365s-4371s. 2006
  66. doi request reprint Volatile fingerprints of cancer specific genetic mutations
    Nir Peled
    Thoracic Cancer Research and Detection Center, Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel
    Nanomedicine 9:758-66. 2013
    ..Studying clinical samples (tissue/blood/breath) will be required as next step in order to determine whether this cell-line study can be translated into a clinically useful tool...